Abstract
Hypophosphatemic osteomalacia is a rare metabolic bone disease in adults, most commonly caused by acquired conditions. Clinically, it may present with widespread musculoskeletal pain, proximal muscle weakness, and gait disturbance, often mimicking rheumatologic disorders. Tenofovir disoproxil fumarate, a widely used nucleotide reverse transcriptase inhibitor in the treatment of human immunodeficiency virus infection, may rarely cause hypophosphatemia and osteomalacia due to proximal renal tubular dysfunction. We report a 33-year-old male patient who presented with progressively worsening diffuse bone and muscle pain, proximal muscle weakness, and difficulty walking over one year and was diagnosed with tenofovir-associated hypophosphatemic osteomalacia. Laboratory evaluation revealed marked hypophosphatemia, phosphaturia, and elevated alkaline phosphatase and parathyroid hormone levels. After discontinuation of tenofovir and initiation of phosphate and active vitamin D supplementation, both clinical symptoms and laboratory abnormalities improved significantly. This case highlights hypophosphatemic osteomalacia as a potentially overlooked complication of tenofovir therapy.